Now showing items 1-2 of 2

  • Bioluminescent imaging of Cdk2 inhibition in vivo 

    Zhang, Guo-Jun; Safran, Michal; Wei, Wenyi; Sorensen, Erik; Lassota, Peter; Zhelev, Nikolai Z.; Neuberg, Donna S.; Shapiro, Geoffrey; Kaelin Jr, William G. (Nature Publishing Group, 2004-05)
    Many proteins and pathways of pharmaceutical interest impinge on ubiquitin ligases or their substrates. The cyclin-dependent kinase (Cdk) inhibitor p27, for example, is polyubiquitylated in a cell cycle−dependent manner ...
  • Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance 

    Khalil, Hilal S.; Mitev, Vanio; Vlaykova, Tatyana; Cavicchi, Laura; Zhelev, Nikolai Z. (Elsevier, 2015-03-06)
    Seliciclib (R-Roscovitine) was identified as an inhibitor of CDKs and has undergone drug development and clinical testing as an anticancer agent. In this review, the authors describe the discovery of Seliciclib and give a ...